Previous Video Next Video

video thumbnail

Absolute Risk Reduction vs Relative Risk Reduction

Duration: 19:03

Write A New Comment

0 Comments

Absolute Risk Reduction vs Relative Risk Reduction

Relative risk, relative and absolute risk reduction, number needed to treat and confidence intervals
https://www.ncbi.nlm.nih.gov/books/NBK63647/

Common pitfalls in statistical analysis: Absolute risk reduction, relative risk reduction, and number needed to treat
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763519/

In this video Dr.Mobeen will discuss:

1. Explanation regarding risk reduction. (1:17)

2. Absolute risk reduction. (3:26)

3. Relative risk. (6:14)

4. Relative risk reduction. (8:53)

5. Explanation with Pfizer vaccine example. (14:09)

Following answers are created by ChatGPT. Occasionally the answer may be harmful, incorrect, false, misleading, incomplete, or limited in knowledge of world. Please contact your doctor for all healthcare decisions. Also, double check the answer provided by the AI below.

Please login to access this content.

Don't have an account?

See Plans

Instructors

COVID-19

Videos in Course
Favourite Videos

Epstein Barr Virus (EBV) - Long COVID

37:38

Dr. Mobeen Syed

Epstein Barr Virus (EBV) Serology

34:00

Dr. Mobeen Syed

Epstein Barr Virus Prevalence in Long COVID

19:16

Dr. Mobeen Syed

Epstein Barr Virus Reactivation in COVID

23:28

Dr. Mobeen Syed

Absolute Risk Reduction vs Relative Risk Reduction

19:03

Dr. Mobeen Syed

0.50 CME

Introduction To P Values and Power

26:02

Dr. Mobeen Syed

COVID-19 Causes Long-Term Blood Cell Changes

26:24

Dr. Mobeen Syed

Early COVID Has Signs For Severe and Long Haul Outcomes

13:48

Dr. Mobeen Syed

COVID-19 Primarily A Vascular Disease

24:08

Dr. Mobeen Syed

New Technique To Study COVID Pathology (High Parameter Imaging Mass Cytometry)

24:49

Dr. Mobeen Syed

COVID Long Haulers - Mast Cell Activation Syndrome (MCAS) Part - 1

27:12

Dr. Mobeen Syed

COVID Long Haulers - Mast Cell Activation Syndrome (MCAS) - Part 2 (Symptoms and Management)

31:05

Dr. Mobeen Syed

0.25 CME

Brain Fog and Other Symptoms In Long Haulers

21:29

Dr. Mobeen Syed

0.50 CME

Defeat Brain Fog With New Neurons - A Review of Neurogenesis

36:26

Dr. Mobeen Syed

COVID-19 and Sickle Cell, Thalassemia, and Hemophilia (Full Session)

45:16

Dr. Mobeen Syed

0.50 CME

Natural Killer (NK) Cells

28:11

Dr. Mobeen Syed

CDC Study - Who Is At Risk of Severe COVID-19

31:59

Dr. Mobeen Syed

0.25 CME

Brain Fog and Other Symptoms In Long Haulers

21:29

Dr. Mobeen Syed

Preprint Study: Spike Protein Accumulates in The Brain

35:34

Dr. Mobeen Syed

Less Long COVID with Omicron Compared to Its Ancestors

19:58

Dr. Mobeen Syed

0.50 CME

Labs to Verify Neurological Toxicity in Long COVID

23:34

Dr. Mobeen Syed

0.25 CME

Elevated Interleukin 6 (IL-6) and Normal C Reactive Protein (CRP)

21:22

Dr. Mobeen Syed

Two Cases of Multiple Sclerosis After mRNA Vaccine

23:08

Dr. Mobeen Syed

0.50 CME

MTHFR Enzyme Deficiency and Cardiovascular Health

28:34

Dr. Mobeen Syed

0.25 CME

Long COVID Improvement after Therapeutic Apheresis

20:19

Dr. Mobeen Syed

Evidence for Aerosol Transfer of SARS-CoV-2–Specific Humoral Immunity

24:10

Dr. Mobeen Syed

FDA Finds Safety Signal after mRNA Vaccine In Children 2-5 Years of Age

17:06

Dr. Mobeen Syed

Related Videos

All information contained in and produced by DrBeen corp is provided for educational purposes only. This information should not be used for the diagnosis or treatment of any health problem or disease.

THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.

Click here for notice and disclaimer.

Copyright © 2015-2025 all rights reserved by DrBeen Corp